Barasa Gelba Sileshi, Fikadu Surafel, Kindie Legesse Alemawi, Wubet Hiwot, Alemu Yesuf Mihret, Abera Wondwossen, Bizuayehu Wube Temesgen
School of Medical Laboratory Science, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia.
HIV AIDS (Auckl). 2020 Jan 29;12:69-77. doi: 10.2147/HIV.S229036. eCollection 2020.
Antiretroviral therapy has resulted in significant reductions in HIV-associated complications by recovering the CD4+ T cell count. Some patients may not be successful in attaining this result, and some may achieve it only after many years of treatment.
This study aimed to assess CD4+ T cell recovery and non-response patterns among HAART experienced HIV-positive patients at the Arsi Negelle health center.
This was a retrospective cross-sectional study conducted among HAART experienced HIV/AIDS patients at Arsi Negelle Health Center from January 01, 2014 to January 06, 2019. Data were documented to a data retrieval form and analyzed with SPSS version 20. Linear regression analysis was used to identify predictors of CD4 count change. A P-value of <0.05 was considered significant.
The total median of CD4+ T cells increased from 257 cells/uL at the baseline to 382 cells/uL after 6 months, then to 591 cells/uL after 60 months of treatment. The non-response rate was 22.1% and 23.8% among the total study participants and children of less than 15 years, respectively. Only baseline CD4+ T cell was associated with a change in CD4+ T cell count.
From our study, we can conclude that CD4+ T cell count has recovered in most of the study participants after HAART initiation. The immunological non-response rate of study participants was 22.1% after 12 months on HAART and 7.2% at the end of the study.
抗逆转录病毒疗法通过恢复CD4+T细胞计数,显著降低了与HIV相关的并发症。一些患者可能无法成功实现这一结果,而一些患者可能仅在多年治疗后才能实现。
本研究旨在评估阿尔西内盖勒健康中心接受高效抗逆转录病毒治疗(HAART)的HIV阳性患者的CD4+T细胞恢复情况和无反应模式。
这是一项回顾性横断面研究,于2014年1月1日至2019年1月6日在阿尔西内盖勒健康中心对接受过HAART的HIV/AIDS患者进行。数据记录在数据检索表上,并用SPSS 20版进行分析。采用线性回归分析确定CD4计数变化的预测因素。P值<0.05被认为具有统计学意义。
CD4+T细胞的总中位数从基线时的257个细胞/微升在6个月后增加到382个细胞/微升,然后在治疗60个月后增加到591个细胞/微升。在所有研究参与者和15岁以下儿童中,无反应率分别为22.1%和23.8%。只有基线CD4+T细胞与CD4+T细胞计数的变化有关。
从我们的研究中可以得出结论,在开始HAART后,大多数研究参与者的CD4+T细胞计数已经恢复。在接受HAART 12个月后,研究参与者的免疫无反应率为22.1%,在研究结束时为7.2%。